Research never stops

Prof. Dr Iris Löw-Friedrich

Prof. Dr Iris Löw-Friedrich (born in 1960) was appointed Member of the Supervisory Board on 17 June 2014 for a term of five years. Her current term will expire at the end of the AGM held in the year 2019. Since March 2008, Prof. Dr Iris Löw-Friedrich has been serving as Chief Medical Officer and Executive Vice President responsible for Development at the Executive Committee of UCB S.A., Brussels, Belgium. From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen. From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA. Since April 2014, she has been Member of the Board of Directors at TransCelerate (Chairman of the BOD from Sept. 2015 until Sept. 2017). Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA.

Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000. She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985.